CDiddy, Great find, Thanks for sharing. great

Quote:

---

That represents approximately $20/share in CytoDyn capitalization for just and EUA approval.

---

Quote:

---

Investor’s who are interested in the fastest way to approve should get over their Mild to Moderate tantrum. When it comes to FDA approval for COVID, does it really matter what level of treatment it is approved at initially? Speed and certainty comes first for CytoDyn and the FDA sees the clearest treatment indication for this drug’s effectiveness in more critical patients. The important message in this call that is overlooked is that there is progress and a clearer path to approval which should come about in a reasonable time period as outlined by the company. I for one appreciate the call and view the statements as positive as I think most people in the know do. It is unfortunate that patience is not a strong characteristic trait in investors. However, those that stand firm should be handsomely rewarded upon approval.

---